Flatiron, Myriad partner to integrate cancer test with EMR platform

Computer Digital Cockpit Social

Myriad Genetics and Flatiron Health are partnering to integrate Myriad's MyRisk Hereditary Cancer Test into Flatiron's cloud-based OncoEMR electronic medical record (EMR) platform.

Financial and other terms of the arrangement were not disclosed.

The integration will allow doctors to order the MyRisk test and view results directly in OncoEMR, the firms said in a statement. Flatiron's network includes 4,200 providers at over 800 community-based cancer care locations across the U.S.

According to the companies, the integration is available now to all OncoEMR users. The MyRisk test is the first hereditary cancer test to be integrated into the OncoEMR platform.

Myriad recently entered into five ongoing research partnerships aimed at studying the use of molecular residual disease testing in breast cancer using Myriad's Precise MRD test.

Flatiron has previously integrated tests from companies, including Guardant and Caris, into its OncoEMR platform.

Page 1 of 41
Next Page